Alkermes Plc  

(Public, NASDAQ:ALKS)   Watch this stock  
Find more results for alks
+1.15 (2.54%)
Aug 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 45.53 - 46.88
52 week 27.14 - 80.71
Open 45.66
Vol / Avg. 0.00/760,964.00
Mkt cap 7.38B
P/E     -
Div/yield     -
EPS -1.83
Shares 151.08M
Beta 1.91
Inst. own 98%
Oct 27, 2016
Q3 2016 Alkermes Plc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jul 28, 2016
Q2 2016 Alkermes Plc Earnings Release
Jul 28, 2016
Q2 2016 Alkermes Plc Earnings Call - Webcast
Jun 8, 2016
Alkermes Plc at Goldman Sachs Global Healthcare Conference
Jun 7, 2016
Alkermes Plc at Jefferies Healthcare Conference
Jun 1, 2016
Alkermes Plc Conference Call to Discuss Data and Study Design from FORWARD-3 and FORWARD-4 Studies of ALKS 5461 - Webcast
May 26, 2016
Alkermes Plc Annual Shareholders Meeting (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -24.18% -36.15%
Operating margin -24.14% -35.70%
EBITD margin - -22.08%
Return on average assets -10.57% -12.04%
Return on average equity -15.09% -16.76%
Employees 1,500 -
CDP Score - -


1 Burlington Road, Connaught House
DUBLIN, 00000
+353-1-7728000 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Alkermes Public Limited Company is a biopharmaceutical company. The Company is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of approximately 20 products and a clinical pipeline of product candidates that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis. Its products include ARISTADA, VIVITROL, RISPERDAL CONSTA, INVEGA SUSTENNA/XEPLION & INVEGA TRINZA, AMPYRA/FAMPYRA, BYDUREON, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, Aripiprazole Lauroxil Two-Month Dose, ALKS 7119 and RDB 1450. Its product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release technology.

Officers and directors

Richard F. Pops Chairman, President, and CEO
James M. (Jim) Frates SVP, CFO, and Treasurer
Gordon G. Pugh SVP, COO, and Chief Risk Officer
Richard F. Pops Chairman of the Board, Chief Executive Officer
Age: 52
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Shane M. Cooke President
Age: 52
Bio & Compensation  - Reuters
James M. Frates Chief Financial Officer, Senior Vice President
Age: 47
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Gordon G. Pugh Chief Operating Officer, Senior Vice President, Chief Risk Officer
Age: 57
Bio & Compensation  - Reuters
Kathryn L. Biberstein Executive Vice President, Chief Administrative Officer, Chief Compliance Officer, Secretary
Age: 56
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Elliot W. Ehrich M.D. Executive Vice President, Research and Development and Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
Rebecca J. Peterson Senior Vice President - Corporate Communications
Age: 39
Bio & Compensation  - Reuters